An Open-Label, Double Tympanocentesis Study of Levofloxacin Therapy in Children With, or at High Risk for, Recurrent or Persistent Acute Otitis Media
Authors:
- Adriano ArguedasAAAdriano Arguedas
- Ron DaganRDRon Dagan
- Michael PichicheroMPMichael Pichichero
- Eugene LeibovitzELEugene Leibovitz
- Jeffery BlumerJBJeffery Blumer
- David F. McNeeleyDMDavid F. McNeeley
- Rama MelkoteRMRama Melkote
- Gary J. NoelGNGary J. Noel
- 1 December 2006
- journal article
- clinical trial
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 25 (12) , 1102-1109
Abstract
Levofloxacin has excellent activity against common respiratory pathogens and therefore is likely to be effective in treating children with persistent or recurrent otitis media. The objective of this study was to assess the efficacy and safety of levofloxacin treatment in the eradication of bacterial pathogens from the middle ear fluid (MEF) of children with, or at high risk for, persistent or recurrent otitis media. An open-label multicenter trial was conducted that involved tympanocentesis at entry and selectively 3 to 5 days after starting levofloxacin (10 mg/kg twice a day for 10 days). : Two hundred five children (80% < or =2 years) were enrolled. One child did not have a confirmed diagnosis of acute otitis media and did not return for follow-up visits. Of the remaining 204 children, 94 (46%) had bilateral infection and 63 (31%) were receiving antimicrobials immediately before entry. One hundred five isolates of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Streptococcus. pyogenes were recovered in pure or mixed cultures. All isolates were susceptible to levofloxacin. During-treatment bacterial eradication from MEF occurred in 88% (78 of 89) of bacteriologically evaluable patients, including 90% (65 of 72) of children < or =24 months of age. Bacteria initially isolated from MEF were eradicated in 31 of 37 (84%) children infected with S. pneumoniae and in 54 of 54 (100%) children infected with H. influenzae. Overall, clinical success rate after therapy was 94% for the total study population and 92% for the bacteriologically evaluable population. Levofloxacin was well tolerated. Vomiting (4%) was the most common treatment-limiting adverse event. Levofloxacin was safe and effective in treating and eradicating common bacterial pathogens from MEF in children with, or at risk for, recurrent or persistent otitis media.Keywords
This publication has 22 references indexed in Scilit:
- Safety and Efficacy of Gatifloxacin Therapy for Children with Recurrent Acute Otitis Media (AOM) and/or AOM Treatment FailureClinical Infectious Diseases, 2005
- In Vitro Activities of Levofloxacin and Comparable Agents against Middle Ear Fluid, Nasopharyngeal, and Oropharyngeal Pathogens Obtained from Costa Rican Children with Recurrent Otitis Media or Failing Other Antibiotic TherapyAntimicrobial Agents and Chemotherapy, 2005
- Changes in Frequency and Pathogens Causing Acute Otitis Media in 1995–2003The Pediatric Infectious Disease Journal, 2004
- Microbiology of otitis media in Costa Rican children, 1999 through 2001The Pediatric Infectious Disease Journal, 2003
- Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failureThe Pediatric Infectious Disease Journal, 2003
- Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis studyThe Pediatric Infectious Disease Journal, 2003
- High-Dose Azithromycin versus High-Dose Amoxicillin-Clavulanate for Treatment of Children with Recurrent or Persistent Acute Otitis MediaAntimicrobial Agents and Chemotherapy, 2003
- Penicillin-resistant Streptococcus pneumoniae in acute otitis mediaThe Pediatric Infectious Disease Journal, 1995
- Otitis MediaClinical Infectious Diseases, 1994
- Epidemiology of Otitis Media During the First Seven Years of Life in Children in Greater Boston: A Prospective, Cohort StudyThe Journal of Infectious Diseases, 1989